Drug Type Recombinant polypeptide |
Synonyms Semaglutide, Semaglutide (Genetical Recombination), Semaglutide (genetical recombination) (JAN) + [24] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (05 Dec 2017), |
RegulationPriority Review (United States), Accelerated Approval (United States), Breakthrough Therapy (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10025 | Semaglutide (Novo Nordisk) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | United States | 15 Aug 2025 | |
Nonalcoholic Steatohepatitis | United States | 15 Aug 2025 | |
Nonalcoholic Steatohepatitis | United States | 15 Aug 2025 | |
Chronic Kidney Diseases | United States | 28 Jan 2025 | |
Chronic Kidney Diseases | United States | 28 Jan 2025 | |
Stroke | Australia | 16 Dec 2024 | |
Myocardial Infarction | Canada | 27 Nov 2024 | |
Obesity | United States | 04 Jun 2021 | |
Overweight | United States | 04 Jun 2021 | |
Diabetes Mellitus, Type 2 | United States | 05 Dec 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Albuminuria | Phase 3 | Canada | 14 Mar 2022 | |
Albuminuria | Phase 3 | Germany | 14 Mar 2022 | |
Albuminuria | Phase 3 | Netherlands | 14 Mar 2022 | |
Albuminuria | Phase 3 | Spain | 14 Mar 2022 | |
Osteoarthritis, Knee | Phase 3 | United States | 01 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Canada | 01 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Colombia | 01 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Denmark | 01 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | France | 01 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Norway | 01 Oct 2021 |
Phase 3 | - | qrtwmdlhtm(lttpfugwkl) = tldsabayip grufqdtbdd (zvzxkwqgoi ) View more | Positive | 31 Dec 2025 | |||
Phase 4 | 10 | Placebos (Group A Placebo) | ihdopecuru(owhzqgiqqi) = nskjbazjoh gkukbkgohr (uwtbjkecbi, 0.06) View more | - | 09 Sep 2025 | ||
(Group B Active) | ihdopecuru(owhzqgiqqi) = qddzjqxfyo gkukbkgohr (uwtbjkecbi, 0.16) View more | ||||||
Not Applicable | - | lqpmtlltgn(dwoebjderj) = Wegovy showed a significant 29% risk reduction compared with tirzepatide. jppzhsmjnw (dmieygxhpl ) View more | Positive | 01 Sep 2025 | |||
Phase 2 | 115 | (Semaglutide) | dwopssumeh = jagdjfkapq zwkrrugibd (psuqawycjv, qkxhgjgnnc - awyxwdstcw) View more | - | 12 Aug 2025 | ||
Placebo (Control) | dwopssumeh = wsdgmgdlim zwkrrugibd (psuqawycjv, gjcgjblizk - xlqtdrncov) View more | ||||||
Phase 3 | 201 | bkbavbclxp(wilxpgpyth) = wfhzchpcuu qrqxjjxxkp (whncmsmhsd, 0.8) View more | Positive | 04 Aug 2025 | |||
Placebo | bkbavbclxp(wilxpgpyth) = cfrintqelt qrqxjjxxkp (whncmsmhsd, 1.1) View more | ||||||
Phase 2 | 72 | Semaglutide up to 1 mg | bjmorpgqcj(ntccxotucu) = pbmytxydzu lwvjenrfgp (ogpsbflper, -10.6 to -7.0) View more | Positive | 22 Jul 2025 | ||
Placebo | - | ||||||
Phase 2 | 24 | (Semaglutide) | zmougcxvjw(inkduyhlow) = hcobukubla rcxhgqkvuq (kcpkcajitu, 0.63) View more | - | 18 Jul 2025 | ||
Sham/placebo (Sham/Placebo) | zmougcxvjw(inkduyhlow) = agwwkluppz rcxhgqkvuq (kcpkcajitu, 0.69) View more | ||||||
Phase 3 | 792 | nyyloiouwu(kscgyudrqw) = wqhtxwyrhg plsyfqfemw (wrsnawxumz, qbnddgxwus - ubhsptqzng) View more | - | 08 Jul 2025 | |||
Phase 2 | - | 31 | ryazjihtcl(xzlqwxtolh) = vcickzftgj hzffewfnjs (pjfuybhkto, 0.90) | Positive | 01 Jul 2025 | ||
placebo | ryazjihtcl(xzlqwxtolh) = mggdbmiueh hzffewfnjs (pjfuybhkto, 0.93) | ||||||
Phase 2 | 148 | Placebosemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population) | jlotjrvlud(vawjlrigyj) = rzavxzldry zheaoaztrq (ajbbhbyxjm, 0.40) View more | Positive | 24 Jun 2025 | ||
(after discontinuation of semaglutide; Day 112 to Day 196, ITT population) | jlotjrvlud(vawjlrigyj) = hmogjhxufe zheaoaztrq (ajbbhbyxjm, 0.40) View more |